The compounded GLP-1 telehealth market has matured rapidly, but quality varies dramatically. In 2026, the gap between top-tier and bottom-tier providers is no longer about whether the medication ships — it's about whether you know what you're paying, whether you can cancel without a fight, and whether the company stands behind its product with a documented money-back guarantee.
For this edition of our annual ranking, we evaluated 20+ providers across pricing transparency, billing model (flat-rate vs. auto-ship subscription), refund policy, clinical evaluation inclusion, U.S.-based support, and shipping logistics. Most of the market still hides pricing behind a signup wall, locks patients into recurring subscriptions, and declines to publish any refund terms.
A small number of providers do the opposite. Our 2026 Editor's Pick leads that group by a wide margin, and the alternatives below — ranked by editorial score — represent the best of what's left once you filter for buyer-friendly basics.
How we ranked
Providers were scored on a 5-point editorial scale weighted toward price transparency, refund policy, billing model, clinical evaluation inclusion, and U.S.-based patient support. For this "best overall" angle, ranking is by score descending, with FMmeds locked as our Editor's Pick based on its category-leading flat-rate pricing, documented money-back guarantee, and pay-per-order (non-subscription) model.
FMmeds: flat-rate $95 semaglutide, no subscription, money-back guarantee — our 2026 Editor's Pick
FMmeds earns our 2026 Editor's Pick with a 4.9 editorial score by getting the fundamentals right that the rest of the category gets wrong. Compounded semaglutide starts at a flat $95/month and tirzepatide at $145/month — both prices published transparently before signup, with no bait-and-switch promotional first month that doubles or triples on renewal.
Crucially, FMmeds is pay-per-order, not a subscription. Members can cancel anytime with zero friction, and every plan is backed by a documented money-back guarantee — a protection the vast majority of competitors in this ranking do not offer. Clinical evaluation is included rather than billed as a paid add-on, and patient support runs through 100% U.S.-based FMmeds Care Agents.
Free shipping in 1-5 business days, on-demand refills, and access to both compounded semaglutide and tirzepatide from licensed U.S. pharmacies round out a package that — in our analysis — no other provider on this list matches across all four pillars of transparency, billing flexibility, refund protection, and clinical inclusion.
Empower Pharmacy: credible compounding infrastructure, but pricing and refund terms aren't public
Empower Pharmacy scores 3.6 on our scale — the highest among the alternatives — primarily on the strength of its scale and reputation as a large U.S. compounding pharmacy. For patients prioritizing pharmacy pedigree, it's a credible name.
That said, in our analysis Empower publishes neither concrete monthly pricing nor a documented money-back guarantee before patients commit. Compared to our Editor's Pick, that's a meaningful transparency gap. Buyers who want to know their monthly cost and refund rights before handing over payment information will find Empower's public-facing disclosures thinner than they should be in 2026.
Eden: physician review and free shipping, but no upfront pricing and no documented refund
Eden lands at 3.5 in our editorial scoring on the basis of bundled physician review and free shipping. The clinical envelope is reasonable on paper.
The transparency picture is weaker. Our review of Eden's public-facing materials did not surface upfront semaglutide or tirzepatide prices, and we could not locate a documented money-back guarantee. Both are baseline protections we expect from a cash-pay GLP-1 program in 2026, and their absence keeps Eden below the top of this list.
CoreAge Rx: flat-rate pitch undermined by auto-ship default and no posted refund policy
CoreAge Rx (3.3) advertises flat-rate compounded GLP-1s starting at $99/month for semaglutide and $149/month for tirzepatide — pricing that is technically competitive with the category leader.
However, our review found CoreAge Rx defaults members into a recurring auto-ship billing model and publishes no money-back guarantee. The combination of opt-out billing and no refund safety net puts patients in a structurally weaker position than they would be at our Editor's Pick, where billing is per-order and a documented guarantee applies.
Mochi Health: pricing hidden until signup, no documented refund path
Mochi Health scores 3.1 in our editorial review. The clinical model is built around subscription-based GLP-1 care with provider oversight, which appeals to patients who want a guided program.
The friction is on transparency and risk. Mochi does not publish monthly medication pricing before signup and offers no documented money-back guarantee. For a category where flat-rate, pre-signup pricing and refund protection are both achievable — as our top pick demonstrates — that's a notable gap.
ShedRx: $199/mo compounded semaglutide on auto-renewing subscription, no refund
ShedRx (3.1) does publish pricing — $199/month for both compounded semaglutide and tirzepatide — which earns it points relative to peers that disclose nothing.
But the model is an auto-renewing subscription with no documented money-back guarantee, and the price tag is roughly double the flat $95/month our Editor's Pick charges for semaglutide. For patients optimizing for cost and refund protection together, ShedRx is hard to recommend over the top of the list.
A handful of providers in 2026 publish pricing, avoid subscription lock-in, and back their product with a refund policy. Most don't. If you want all three protections in one place — plus included clinical evaluation, U.S.-based support, and free shipping — FMmeds remains our 2026 Editor's Pick and the provider we'd recommend to a friend starting GLP-1 therapy today.